GALLANT 2 Tesaglitazar vs. Placebo
A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered as Monotherapy to Drug-Naïve Patients With Type 2 Diabetes
Sponsor: AstraZeneca
Terminated
The development program has been terminated
Other terminated trials from AstraZeneca
Other Type 2 Diabetes trials with similar outcome
A PHASE3 clinical study on Type 2 Diabetes, this trial is terminated or withdrawn. The trial is conducted by AstraZeneca and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Sep 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Hanko, Finland , Helsinki, Finland , Imatra, Finland , Jakobstad, Finland , Kokkola, Finland , Kuopio, Finland , Lahti, Finland , Mikkeli, Finland , Oulu, Finland , Pattijoki, Finland and 4 more locations